Subscribe to RSS
Download PDF
DOI: 10.4103/ijmpo.ijmpo_85_19
Rapidly Progressive Pleuro-parenchymal Fibroelastosis Secondary to Cyclophosphamide Chemotherapy
Financial support and sponsorship Nil.
Abstract
Pleuroparenchymal fibroelastosis (PPFE) is a rare progressive interstitial lung disease presenting with predominantly upper-lobe pleural thickening and pulmonary fibrosis. While most cases are idiopathic, it is rarely seen as a complication of infection or following chemotherapy, radiation therapy, and bone marrow transplant. We describe a case of early onset and rapidly progressive PPFE as a complication of cyclophosphamide chemotherapy.
Publication History
Received: 02 April 2019
Accepted: 06 June 2019
Article published online:
28 June 2021
© 2020. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 Hoyt DG, Lazo JS. Early increases in pulmonary mRNA encoding procollagens and transforming growth factor-beta in mice sensitive to cyclophosphamide-induced pulmonary fibrosis. J Pharmacol Exp Ther 1989; 249: 38-43
- 2 Watanabe K. Pleuroparenchymal fibroelastosis: Its clinical characteristics. Curr Respir Med Rev 2013; 9: 299-237
- 3 Frankel SK, Cool CD, Lynch DA, Brown KK. Idiopathic pleuroparenchymal fibroelastosis: Description of a novel clinicopathologic entity. Chest 2004; 126: 2007-13
- 4 Travis WD, Costabel U, Hansell DM, King TEJr, Lynch DA, Nicholson AG. et al. An official American thoracic society/European respiratory society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 2013; 188: 733-48
- 5 Hirota T, Yoshida Y, Kitasato Y, Yoshimi M, Koga T, Tsuruta N. et al. Histological evolution of pleuroparenchymal fibroelastosis. Histopathology 2015; 66: 545-54
- 6 Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A. et al. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J 2014; 44: 523-7
- 7 von der ThüsenJH, Hansell DM, Tominaga M, Veys PA, Ashworth MT, Owens CM. et al. Pleuroparenchymal fibroelastosis in patients with pulmonary disease secondary to bone marrow transplantation. Mod Pathol 2011; 24: 1633-9
- 8 Reddy TL, Tominaga M, Hansell DM, von der ThusenJ, Rassl D, Parfrey H. et al. Pleuroparenchymal fibroelastosis: A spectrum of histopathological and imaging phenotypes. Eur Respir J 2012; 40: 377-85
- 9 Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med 1996; 154: 1851-6
- 10 Hata A, Nakajima T, Yoshida S, Kinoshita T, Terada J, Tatsumi K. et al. Living donor lung transplantation for pleuroparenchymal fibroelastosis. Ann Thorac Surg 2016; 101: 1970-2
- 11 Behr J, Neuser P, Prasse A, Kreuter M, Rabe K, Schade-Brittinger C. et al. Exploring efficacy and safety of oral pirfenidone for progressive, non-IPF lung fibrosis (RELIEF) – A randomized, double-blind, placebo-controlled, parallel group, multi-center, phase II trial. BMC Pulm Med 2017; 17: 122